THERAPEUTICS
High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimers disease
| The first 150 words of the full text of this article appear below. |
Does high dose vitamin B supplementation have an effect on cognitive decline in people with Alzheimers disease?
409 people with mild to moderate probable Alzheimers disease (NINCDS-ADRDA criteria; mean age 76 years; 56% female; 41% multivitamin users; 91% using cholinesterase inhibitors). Exclusions: <50 years old; medically unstable, Mini-Mental State Examination score <14 or >26; vitamin B12 or folate insufficiency (vitamin B12 <175 pg/ml; folate <4.2 ng/ml); renal insufficiency (serum creatine
2.0 mg/dl); daily vitamin supplementation with >400 µg folic acid; used sedatives, anti-Parkinsons or drugs with anticholinergic effects in the past 2 months; or recent investigational treatment for Alzheimers disease. Stable use of cholinesterase inhibitors or memantine was allowed if it had been ongoing for at least 3 months.
40 sites across the USA; recruitment: February 2003 to December 2006.
High dose vitamin B supplementation (5 mg folic acid, 1 mg vitamin B12 (cyanocobalamin) and 25 mg vitamin B6 (pyridoxine
Murray Royal Hospital, Perth, UK
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
